Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8543, Japan.
Department of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan.
ESC Heart Fail. 2022 Oct;9(5):3435-3451. doi: 10.1002/ehf2.14059. Epub 2022 Jul 18.
The role of necroptosis in dilated cardiomyopathy (DCM) remains unclear. Here, we examined whether phosphorylation of mixed lineage kinase domain-like protein (MLKL), an indispensable event for execution of necroptosis, is associated with the progression of DCM.
Patients with DCM (n = 56, 56 ± 15 years of age; 68% male) were enrolled for immunohistochemical analyses of biopsies. Adverse events were defined as a composite of death or admission for heart failure or ventricular arrhythmia. Compared with the normal myocardium, increased signals of MLKL phosphorylation were detected in the nuclei, cytoplasm, and intercalated discs of cardiomyocytes in biopsy samples from DCM patients. The phosphorylated MLKL (p-MLKL) signal was increased in enlarged nuclei or nuclei with bizarre shapes in hypertrophied cardiomyocytes. Nuclear p-MLKL level was correlated negatively with septal peak myocardial velocity during early diastole (r = -0.327, P = 0.019) and was correlated positively with tricuspid regurgitation pressure gradient (r = 0.339, P = 0.023), while p-MLKL level in intercalated discs was negatively correlated with mean left ventricular wall thickness (r = -0.360, P = 0.014). During a median follow-up period of 3.5 years, 10 patients (18%) had adverse events. To examine the difference in event rates according to p-MLKL expression levels, patients were divided into two groups by using the median value of nuclear p-MLKL or intercalated disc p-MLKL. A group with high nuclear p-MLKL level (H-nucMLKL group) had a higher adverse event rate than did a group with low nuclear p-MLKL level (L-nucMLKL group) (32% vs. 4%, P = 0.012), and Kaplan-Meier survival curves showed that the adverse event-free survival rate was lower in the H-nucMLKL group than in the L-nucMLKL group (P = 0.019 by the log-rank test). Such differences were not detected between groups divided by a median value of intercalated disc p-MLKL. In δ-sarcoglycan-deficient (Sgcd ) mice, a model of DCM, total p-MLKL and nuclear p-MLKL levels were higher than in wild-type mice.
The results suggest that increased localization of nuclear p-MLKL in cardiomyocytes is associated with left ventricular diastolic dysfunction and future adverse events in DCM.
细胞程序性坏死(Necroptosis)在扩张型心肌病(DCM)中的作用尚不清楚。本研究旨在探讨混合谱系激酶结构域样蛋白(MLKL)磷酸化,即执行细胞程序性坏死所必需的事件,是否与 DCM 的进展相关。
本研究纳入了 56 名 DCM 患者(56±15 岁;68%为男性)进行活检的免疫组化分析。不良事件定义为死亡或因心力衰竭或室性心律失常入院的复合终点。与正常心肌相比,DCM 患者活检样本中的心肌细胞细胞核、细胞质和闰盘均可检测到 MLKL 磷酸化信号增强。在肥大的心肌细胞中,可见增大的细胞核或形状奇异的细胞核内存在磷酸化 MLKL(p-MLKL)信号增强。核内 p-MLKL 水平与舒张早期室间隔峰值心肌速度呈负相关(r=-0.327,P=0.019),与三尖瓣反流压力梯度呈正相关(r=0.339,P=0.023),而闰盘的 p-MLKL 水平与左心室壁平均厚度呈负相关(r=-0.360,P=0.014)。在中位数为 3.5 年的随访期间,10 名患者(18%)发生了不良事件。为了检验根据 p-MLKL 表达水平的事件发生率差异,我们将患者按核内 p-MLKL 或闰盘 p-MLKL 的中位数分为两组。核内 p-MLKL 水平较高的组(H-nucMLKL 组)的不良事件发生率高于核内 p-MLKL 水平较低的组(L-nucMLKL 组)(32% vs. 4%,P=0.012),Kaplan-Meier 生存曲线显示 H-nucMLKL 组的不良事件无事件生存率低于 L-nucMLKL 组(log-rank 检验,P=0.019)。按闰盘 p-MLKL 中位数划分的两组之间未发现差异。在δ-肌聚糖缺陷(Sgcd)小鼠(DCM 模型)中,总 p-MLKL 和核内 p-MLKL 水平均高于野生型小鼠。
研究结果表明,心肌细胞内核 p-MLKL 的定位增加与 DCM 患者的左心室舒张功能障碍和未来不良事件相关。